Hemostatic management of an infant with severe hemophilia A and tetralogy of Fallot for cardiac bypass surgery.
We present the hemostatic management of severe hemophilia A of an infant with high risk of inhibitor development who underwent cardiac surgery for correction of tetralogy of Fallot. Continuous infusion of recombinant factor VIII resulted in good hemostasis during surgery and postoperatively. Unfortunately, the patient had inhibitor development 2 months after cardiothoracic surgery. Although cardiac surgery is successful, exposure to factor concentrates in severe hemophilia early in life might predispose a patient to inhibitor development.
Rodriguez
Vilmarie
V
Division of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. rodriguez.vilmarie@mayo.edu
Burkhart
Harold M
HM
Schmidt
Kirstin A
KA
Pruthi
Rajiv K
RK
D006348:Cardiac Surgical Procedures; D005169:Factor VIII / Q000008:administration & dosage* / Q000032:analysis / Q000037:antagonists & inhibitors; D006467:Hemophilia A / Q000097:blood / Q000150:complications*; D006488:Hemostasis, Surgical; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D013771:Tetralogy of Fallot / Q000150:complications / Q000601:surgery*
D011994:Recombinant Proteins; D005169:Factor VIII